Time filter

Source Type

Wang Q.,Peking University | Liu H.,Hematology Laboratories | Zhang X.,Hematology Laboratories | Liu Q.,Peking University | And 4 more authors.
Blood | Year: 2010

Donor lymphocyte infusion is an alternative treatment for Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPDs) but with risk of graft-versushost diseases (GVHDs). According to the fetal-maternal microchimerism tolerance, we assumed that maternal lymphocyte infusion may be effective without causing GVHD. In 54 cases when a child required cytotherapy or hematopoietic stem cell transplantation, we studied the mother for child-mother microchimerism with use of insertion-deletion polymorphisms as allogeneic markers and a combination of nested polymerase chain reaction (PCR) and real-time quantitative PCR. Thirteen mothers were child-microchimerismpositive at the ratio of 10-5-10-3. Among them, 5 children had non-transplantassociated, EBV+ T-cell LPD. In these 5 cases, high doses of human leukocyte antigen-haploidentical maternal peripheral blood mononuclear cells (> 108/kg/infusion) were infused 1-4 times. Symptoms of all 5 patients improved between 3 and 10 days after the infusion; thereafter, 3 cases showed complete remission for 6-18 months without further therapy and 2 had partial remission. During the period of observation, none developed obvious GVHD. By quantitative PCR, in some patients maternal cells were found to be eliminated or decreased after infusions, indicating existence of host-versusgraft reaction. We suggest that high doses of mother's lymphocyte infusion may be an effective and safe treatment for nontransplant-associated EBV+ T-cell LPD. © 2010 by The American Society of Hematology.

Kruger M.C.,Massey University | Ha P.C.,Clinical Center and Basic Research | Todd J.M.,Fonterra Brands Ltd. | Kuhn-Sherlock B.,Fonterra Research Center | And 4 more authors.
European Journal of Clinical Nutrition | Year: 2012

Background/objectives:Risk for developing osteoporosis increases in Asia. The purpose of the study was to evaluate the impact of a high-calcium vitamin D fortified milk (HCM) intervention on parathyroid hormone (PTH) levels, vitamin D status and markers of bone turnover in postmenopausal Chinese women.Subjects/methods:Sixty three women (55 years) were assigned to receive two servings of either a calcium/vitamin D fortified milk or a control drink for 12 weeks. PTH, serum 25 (OH)D levels, C-telopeptide of type I collagen (CTX) levels and procollagen type I N-terminal propeptide (PINP) were measured at baseline, 2, 8 and 12 weeks of supplementation.Results:Daily calcium intake at baseline ranged between 260 and 482 mg for the HCM, and 252 and 692 mg for the control group. HCM improved serum 25 (OH)D levels significantly (33.13-39.49 nmol/l), while remaining similar in the control group (29.27-28.21 nmol/l). The difference between the groups were significant at week 2, 8 and 12. The percentage change in PTH levels in the HCM group was significant from week 2 onwards compared to the control drink (P0.017, P0.05 and P0.001 at weeks 2, 8 and 12, respectively). Plasma CTX of the HCM group reduced by 25% between weeks 0 and 2, remaining significantly lower and at similar levels up to week 12. The difference between the HCM and control group for PINP reached significance at weeks 8 (P0.011) and 12 (P0.003).Conclusions:The HCM intervention significantly improved vitamin D status and reduced bone turnover over 12 weeks in postmenopausal Chinese women. © 2012 Macmillan Publishers Limited.

Zhang F.,Beijing University of Technology | Yang Z.,Beijing University of Technology | Yang Z.,North University of China | Cao M.,Beijing University of Technology | And 10 more authors.
Cancer Letters | Year: 2014

The expression of miR-203 has been reported to be significantly down-regulated in esophageal cancer. We showed here that overexpression of miR-203 in esophageal cancer cells dramatically increased cell apoptosis and inhibited cell proliferation, migration and invasion as well as tumor growth and down-regulated miR-21 expression. We subsequently identified that small GTPase Ran was a target gene of miR-203. Furthermore, Ran restoration partially counteracted the tumor suppressive effects of miR-203 and increased miR-21 expression. Taken together, our findings suggest that miR-203 may act as novel tumor suppressor in esophageal cancer through down-regulating the expression of Ran and miR-21. © 2013 The Authors.

Chen X.,Beijing University of Technology | Zhang F.,Beijing University of Technology | He X.,Beijing Friendship Hospital | Xu Y.,Beijing University of Technology | And 8 more authors.
Injury | Year: 2013

Introduction: A potent mesenchymal stem cell (MSC) population was recently isolated from the Wharton's jelly of human umbilical cord (UC). The aim of the current experiments was to determine the potential of human UC-derived MSC (UC-MSC) in cartilage healing. Materials and methods: Chondrogenic differentiation of collagen hydrogel-embedded cells was induced in standard chondrocyte conditioning medium and further detected by real-time PCR, histochemistry and immunohistochemistry analyses. Cell viability and apoptosis of the MSCs in the collagen I hydrogels were monitored using apoptosis detection kit. Results: Cells isolated from UC were positive for MSC biomarkers and negative for haematopoietic lineage and endothelial biomarkers and possess the capacity to differentiate along osteogenic lineage. UC-MSCs embedded in collagen hydrogel can undergo chondrogenesis characterised by significantly increased expressions of collagen II, aggrecan, COMP (cartilage oligomeric matrix protein) and sox9 after exposed cells-embedded hydrogels to chondrogenic factors. The most of cells remained viable throughout the hydrogels after 3 weeks of cultivation in chondrogenic differentiation medium. Conclusions: Collagen hydrogel can provide an appropriate 3-D environment for the chondrogenesis of UC-MSCs. UC-MSCs embedded in biocompatible scaffold may have great potential for cartilage engineering. © 2012 Elsevier Ltd.

Wang P.,Peking Union Medical College | Yu X.-M.,Beijing Friendship Hospital
Diagnostic Cytopathology | Year: 2012

Primary breast lymphomas are uncommon. All reported primary breast lymphomas were in the breast parenchyma. Here we reported the first case of primary nipple lymphoma in a 76-year-old woman initially diagnosed using a modified fine-needle aspiration method. The aspirated material by this method had yielded adequate material for both cytomorphologic and flow cytometric analysis, as well as for molecular analysis of light chain rearrangement. In smears the atypical lymphocytes were predominantly middle-sized with irregular nuclei. Scattered large centroblast or immunoblast-like cells, a few reactive lymphocytes, histocytes, and few plasma cells were also observed. These findings suggested a low-grade lymphoma that was further confirmed by flow cytometry (CD19+/CD3-, positive for cytoplasmic kappa light chain but negative for lambda light chain) and molecular analysis (monoclonal rearrangement of immunoglobulin kappa chain). Immunohistochemical stains performed on the excised specimen showed that the tumor cells were positive for CD20 and CD79a but negative for cytokeratin, CD3, CD5, CD10, CD23, CD43, CD45RO, bcl-6, and cyclin-D1. The Ki-67 proliferation index was less than 20%. Taking these together, the case was diagnosed as a primary MALT lymphoma of the nipple. FNA usually provides a better cell morphology than tissue sections, but pathologists have to face the sampling error and lack of immunophenotype information when subtyping lymphoma issues using FNA. With the help of flow cytometry and molecular analysis, more and more trials haveproved the accuracy of FNA in diagnosis of lymphomas. Therefore, FNA could play an informative and diagnostic role indiagnosis of lymphoma. Copyright © 2010 Wiley Periodicals, Inc.

Discover hidden collaborations